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In nonrandomised studies, inferring causal effects requires appropriatemethods
for addressing confounding bias. Although it is common to adopt propen-
sity score analysis to this purpose, prognostic score analysis has recently been
proposed as an alternative strategy.While both approacheswere originally intro-
duced to estimate causal effects for binary interventions, the theory of propensity
score has since been extended to the case of general treatment regimes. Indeed,
many treatments are not assigned in a binary fashion and require a certain extent
of dosing. Hence, researchers may often be interested in estimating treatment
effects across multiple exposures. To the best of our knowledge, the prognos-
tic score analysis has not been yet generalised to this case. In this article, we
describe the theory of prognostic scores for causal inference with general treat-
ment regimes. Our methods can be applied to compare multiple treatments
using nonrandomised data, a topic of great relevance in contemporary evalua-
tions of clinical interventions. We propose estimators for the average treatment
effects in different populations of interest, the validity of which is assessed
through a series of simulations. Finally, we present an illustrative case in which
we estimate the effect of the delay to Aspirin administration on a composite
outcome of death or dependence at 6 months in stroke patients.
KEYWORDS
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1 INTRODUCTION
In clinical research, experimental studies are generally considered as the gold standard for inferring causal effects of
interventions.1 The most common form is the randomised trial, which involves randomised allocation of a subject's treat-
ment. Unfortunately, the conduct of randomised trials is not always feasible, as there may be operational, financial, or
even ethical constraints to administer a certain treatment. In addition, many randomised trials adopt very narrow enrol-
ment criteria and fail to address the impact of studied interventions in clinical practice.2-4 For this reason, observational
studies may sometimes be regarded as alternative sources for assessing the relative effect of medical interventions.
Evidently, it may come as no surprise that inferring causal effects from nonrandomised data is no easy task. Foremost,
confounding bias is likely to occur because treatment exposure usually depends on patient characteristics and preferences
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of care givers. This implies that substantial efforts are needed to handle the presence of systematic differences in covariate
distributions across treated individuals. A common framework to address confounding bias is to mimic randomisation
by propensity score analysis, which aims to restore the balance in the subjects' baseline covariate distributions across
the different treatment exposures.5 The prognostic score analysis is a related method that seeks to balance the subjects'
baseline prognosis, rather than their covariates per se.6
Although both propensity and prognostic score analyses share similar assumptions (ie, stable treatment unit value and
absence of hidden bias),5,6 a major advantage of the latter is that it relaxes the positivity assumption,6 This assumption
requires to have observations for all exposures at every value of the observed confounders, whichmight be hardly feasible
in the presence of multiple exposures. Further, because the positivity assumption of propensity score analysis is rarely
evaluated in practice,7,8 prognostic score analysis appears as an appealing alternative to study causal effects in the presence
of multiple treatment exposures.
The growing demand for real-world evidence and large amounts of (high quality) observational data expose the need
for more advanced statistical methods for analysing relative treatment effects. In particular, patients in routine care often
present substantial variation in treatment dosage or drugs for a therapeutic class, and thus, researchers may often be
interested in treatment effect estimation for these multiple exposures. Although the theory of propensity score has been
extended to general treatment regimes, its implementation is not very straightforward as it involves estimation of different
propensity models given the treatment exposure distribution.9-11
In this article, we aim to extend the framework of prognostic scores for causal inference to the case of general treatment
regimes. We present a theoretical framework in Section 2, which is complemented by a simulation study reported in
Section 3, and a study case in Section 4. To illustrate the (potential) advantages of ourmethod,we compare its performance
to the propensity score analysis framework.
2 THEORY AND METHODS
2.1 Causal framework
Using Rubin's notations for causal inference,12 let Yi be the actual (observed) outcome, Xi ∈ A a vector of measured
subject-level covariates and Zi ∈ Z the treatment status. Further, let Z = {z1,… , zT} represent the treatment space for
the exposures. A common notion in causal inference is the concept of “potential outcomes” (or “counterfactuals”), which
refers to the outcomes that would be observed if the individuals were—contrary to the fact—to receive each treatment
exposure. Hence, to any exposure zt then corresponds a potential outcome Y(t)i. Note that according to this formula-
tion, one of the potential outcomes (but no more) is always observed. We can formulate the observed outcome Yi as an
amalgamation of these potential responses to the various possible treatment exposures
Yi =
T∑
t=1
I (Zi = zt)Y(t)i,
where I(Zi = zt) is the indicator function for actually receiving treatment zt. Setting Zi = zt leads to observing Yi = Y(t)i
which refers to consistency.
Causal inference requires the stable treatment unit value assumption (SUTVA); that is, the distribution of potential
outcomes for one individual is independent from the treatment assigned to any other unit.13
Setting zr as the “reference” treatment (eg, standard care), the treatment effect (henceforth TE) caused by any other
treatment zs (∀ s ≠ r) for a given subject is defined as
TE(zs,zr)i = Y(s)i − Y(r)i.
However, it may be clear that TE(zs,zr)i is nonidentifiable in practice because individual subjects cannot simultaneously
experience zs and zr, and thus, either Y(s)i or Y(r)i will obviously remain unobserved. This issue refers to the “fundamental
problem of causal inference” and is equally relevant for randomised and nonrandomised studies.14
Although the lack of counterfactual evidence obfuscates any causal inference at the subject level, treatment effect
estimates can, in fact, be obtained for specific (sub)populations. In this regard, a common quantity of interest is the aver-
age effect caused by treatment zs over zr. Depending on which population the causal effect is to be inferred, different
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estimands can be defined—among these, the most commonly used are the average treatment effect in the entire pop-
ulation (ATE), the average treatment effect in the treated population (ATT), and the average treatment effect in the
“reference” population (ATR). Given that potential outcomes are averaged over (sub)populations, the index i is to be
suppressed in the following equations:
ATEzs,zr = E (Ys − Yr) = E (Ys) − E (Yr)
ATTzs,zr = E (Ys − Yr|Z = zs) = E (Ys|Z = zs) − E (Yr|Z = zs)
ATRzs,zr = E (Ys − Yr|Z = zr) = E (Ys|Z = zr) − E (Yr|Z = zr) .
(In case of binary treatments where Z∈ {0, 1}, taking Z= 0 as reference, the ATR is often referred to as “average treatment
effect in the untreated/control population.”)
Similarly, one can define the effects caused by any other treatment zt over zr, ∀ t ≠ s ≠ r (ie, multiple treatment
exposures), as
ATEzt ,zr = E (Yt − Yr) = E (Yt) − E (Yr)
ATTzt ,zr = E (Yt − Yr|Z = zt) = E (Yt|Z = zt) − E (Yr|Z = zt)
ATRzt ,zr = E (Yt − Yr|Z = zr) = E (Yt|Z = zr) − E (Yr|Z = zr) .
It is important to note that ATEs and ATRs are transitive estimands, in the sense that
ATEzs,zr − ATEzt ,zr = E (Ys) − E (Yr) − E (Yt) + E (Yr)
= E (Ys) − E (Yt)
= ATEzs,zt
and
ATRzs,zr − ATRzt ,zr = E (Ys|Z = zr) − E (Yr|Z = zr) − E (Yt|Z = zr) + E (Yr|Z = zr)
= E (Ys|Z = zr) − E (Yt|Z = zr)
= ATRzs,zt .
This property allows the average effects caused by zt and zs, with respect to zr, to be directly compared and as such to
make inferences on their relative efficacy.
Similarly, transitivity of ATTs requires that ATTzs,zr − ATTzt ,zr = ATTzs,zt . This property, however, generally
does not hold when multiple treatment exposures are available for a certain population. In particular, in non-
randomised studies, treatment allocation is often influenced by multiple covariates, such that the populations eli-
gible to receive zt and zs are likely to differ in terms of covariate distribution. In other words, the expression
E (Ys |Z= zs)− E (Yr |Z= zs)− E (Yt |Z= zt) + E (Yr |Z= zt) is unlikely to collapse to E (Ys |Z= zs)− E (Yt |Z= zs) because,
usually, E (Yr |Z = zs) ≠ E (Yr |Z = zt) and E (Yt |Z = zt) ≠ E (Yt |Z = zs).
For this reason, we argue that ATEs and ATRs might be preferable estimands in case of multiple treatment exposures.
2.2 Prognostic score
For causal inference, Hansen formalised the use of the prognostic score that can be regarded as the “prognostic analogue
of the propensity score.”6 While the propensity score analysis seeks to ensure propensity balance on es(X)= Pr (Z= zs |X),5
the prognostic score analysis is aimed at securing a prognostic balance across the treatment arms.6 The framework of
propensity scores demands major assumptions: SUTVA, absence of hidden bias given the set of measured covariates
(ie, Y(·) ⟂ Z ∣ X,X ∈ A), and positivity (ie, 0 < Pr (Z ∈ Z ∣ X) with certainty).5,9 (Note, the contraction of the latter two is
also called “strong ignorability of treatment assignment.”) Similarly, the framework of prognostic scores requires SUTVA,
absence of hidden bias, and a relaxed form of positivity.
Let 𝜓 r(X) be a prognostic score such that Yr ⟂ X ∣ 𝜓 r(X), X ∈ A, A being any measurable set.6 In that sense, 𝜓 r(X) is
sufficient for Yr, which does not necessarily imply it is for Ys—in particular, when effect modification exists, such that
Pr(Ys |Yr, X) ≠ Pr(Ys|Yr).6 In presence of any effect modifier denoted ms,r(X), then {𝜓 r(X),ms,r(X)} is sufficient for Ys
(ie, Ys ⟂ X ∣ 𝜓 r(X),ms,r(X)).6
Hansen's proposition 3 showed that, under the assumption of no hidden bias, Yr ⟂ Z ∣ X,X ∈ A (ie, the measur-
able set includes all relevant confounders), conditioning on 𝜓 r(X) deconfounds the potential response Yr from treatment
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assignment, that is, Yr ⟂ Z ∣ 𝜓 r(X).6 In the absence of effect modifier, it also deconfounds the potential response to zs from
treatment assignment, that is, Ys ⟂ Z ∣ 𝜓 r(X); otherwise, Ys ⟂ Z ∣ 𝜓 r(X), ms,r(X).6 Should there be no hidden bias, then
conditioning on the prognostic score (and effect modifier) allows one to estimate causal effects.
2.3 Identification of causal effects
2.3.1 Average treatment effect in the treated population
Suppose that Yr ⟂ Z ∣ 𝜓 r(X) and Pr{0 < Pr(Z = zr ∣𝜓 r(X))} = 1, then
ATTzs,zr = E (Ys − Yr|Z = zs) = E𝜓r(X)∣Z=zs {E (Y |Z = zs, 𝜓r (X)) − E (Y |Z = zr, 𝜓r (X))} ,
where E𝜓r(X)∣Z=zs denotes the expectation with respect to the distribution of 𝜓 r(X) in the treated population Z = zs.
This corresponds to Hansen's proposition 4,6 the proof of which is the following.
Certainly E (Y |Z = zs,𝜓 r(X)) = E (Ys |Z = zs,𝜓 r(X)) and E (Y |Z = zr,𝜓 r(X)) = E (Yr |Z = zr,𝜓 r(X)). The initial
assumptions imply that E (Yr |Z = zr,𝜓 r(X)) = E (Yr |Z = zs,𝜓 r(X)).
Therefore,
E (Y |Z = zs, 𝜓r (X)) − E (Y |Z = zr, 𝜓r (X)) = E (Ys|Z = zs, 𝜓r (X)) − E (Yr|Z = zs, 𝜓r (X))
= E (Ys − Yr|Z = zs, 𝜓r (X))
from which follows
E𝜓r(X)∣Z=zs {E (Y |Z = zs, 𝜓r (X)) − E (Y |Z = zr, 𝜓r (X))}
= E𝜓r(X)∣Z=zs {E (Ys − Yr|Z = zs, 𝜓r (X))} = E (Ys − Yr|Z = zs) ■
Hereto, conditioning on solely 𝜓 r(X) allows the estimation of ATTzt ,zr , regardless of whether there be effect
modification.
2.3.2 Average treatment effect in the reference population
Suppose in presence of some effect modifier ms,r(X), Ys ⟂ Z ∣ 𝜓 r(X), ms,r(X) and Pr{0 < Pr(Z = zs |𝜓 r(X),ms,r(X))} = 1;
otherwise, in absence of effect modifier, suppose Ys ⟂ Z | 𝜓 r(X) and Pr{0 < Pr(Z = zs |𝜓 r(X))} = 1. Then,
(1) In presence of an effect modifierms,r(X),
ATRzs,zr = E (Ys − Yr|Z = zr)
= E𝜓r(X),ms,r(X)∣Z=zr{E (Y |Z = zs, 𝜓r (X) ,ms,r (X)) − E (Y |Z = zr, 𝜓r (X) ,ms,r (X))}.
(2) Otherwise, in the absence of effect modifier,
ATRzs,zr = E (Ys − Yr|Z = zr)
= E𝜓r(X)∣Z=zr {E (Y |Z = zs, 𝜓r (X)) − E (Y |Z = zr, 𝜓r (X))} .
Here, E𝜓r(X),ms,r(X)∣Z=zr and E𝜓r(X)∣Z=zr denote expectations with respect to the distribution of {𝜓 r(X),ms,r(X)} and 𝜓 r(X),
respectively, in the reference population Z = zr.
Proof. Certainly,E (Y |Z= zs,𝜓 r(X),ms,r(X))=E (Ys |Z= zs,𝜓 r(X),ms,r(X)) andE (Y |Z= zr,𝜓 r(X),ms,r(X))=E (Yr |Z= zr,
𝜓 r(X),ms,r(X)). The initial assumptions imply that E (Ys |Z = zs,𝜓 r(X),ms,r(X)) = E (Ys |Z = zr,𝜓 r(X),ms,r(X)).
Therefore,
E (Y |Z = zs, 𝜓r (X) ,ms,r (X)) − E (Y |Z = zr, 𝜓r (X) ,ms,r (X))
= E (Ys|Z = zr, 𝜓r (X) ,ms,r (X)) − E (Yr|Z = zr, 𝜓r (X) ,ms,r (X))
= E (Ys − Yr|Z = zr, 𝜓r (X) ,ms,r (X))
from which follows
E𝜓r(X),ms,r(X)∣Z=zr{E (Y |Z = zs, 𝜓r (X) ,ms,r (X)) − E (Y |Z = zr, 𝜓r (X) ,ms,r (X))}
= E𝜓r(X),ms,r(X)∣Z=zr{E (Ys − Yr|Z = zr, 𝜓r (X) ,ms,r (X))}
= E (Ys − Yr|Z = zr).
Should there be no effect modifier, thenms,r(X) vanishes from (1), and (2) follows.
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2.3.3 Average treatment effect in the entire population
Suppose simultaneously the assumptions announced in Sections 2.3.1 and 2.3.2, and then,
(1) In presence of an effect modifierms,r(X),
ATEzs,zr = E (Ys − Yr)
= E𝜓r(X),ms,r(X){E (Y |Z = zs, 𝜓r (X) ,ms,r (X)) − E (Y |Z = zr, 𝜓r (X) ,ms,r (X))}.
(2) Otherwise, in the absence of effect modifier,
ATEzs,zr = E (Ys − Yr) = E𝜓r(X) {E (Y |Z = zs, 𝜓r (X)) − E (Y |Z = zr, 𝜓r (X))} .
Here,E𝜓r(X),ms,r(X) andE𝜓r(X) denote expectationswith respect to the distribution of {𝜓 r(X),ms,r(X)} and𝜓 r(X), respectively,
in the entire population.
Proof. Certainly,E (Y |Z= zs,𝜓 r(X),ms,r(X))=E (Ys |Z= zs,𝜓 r(X),ms,r(X)) andE (Y |Z= zr,𝜓 r(X),ms,r(X))=E (Yr |Z=
zr,𝜓 r(X),ms,r(X)).
AssumingYr ⟂Z ∣𝜓 r(X),ms,r(X) and Pr{0< Pr(Z= zr |𝜓 r(X),ms,r(X))}= 1 entails thatE (Y |Z= zr,𝜓 r(X),ms,r(X))=
E (Yr |𝜓 r(X),ms,r(X)). Similarly, assuming Ys ⟂ Z |𝜓 r(X), ms,r(X) and Pr{0 < Pr(Z = zs |𝜓 r(X),ms,r(X))} = 1 entails
that E (Y |Z = zs,𝜓 r(X),ms,r(X)) = E (Ys |𝜓 r(X),ms,r(X)).
Therefore,
E (Y |Z = zs, 𝜓r (X) ,ms,r (X)) − E (Y |Z = zr, 𝜓r (X) ,ms,r (X)) = E (Ys|𝜓r (X) ,ms,r (X)) − E (Yr|𝜓r (X) ,ms,r (X))
from which follows
E𝜓r(X),ms,r(X){E (Y |Z = zs, 𝜓r (X) ,ms,r (X)) − E (Y |Z = zr, 𝜓r (X) ,ms,r (X))}
= E𝜓r(X),ms,r(X){E (Ys|𝜓r (X) ,ms,r (X)) − E (Yr|𝜓r (X) ,ms,r (X))}
= E (Ys − Yr) .
Should there be no effect modifier, thenms,r(X) vanishes from (1), and (2) follows.
Note that, in case of binary treatment, Z ∈ Z = {zs, zr}, this corresponds to Hansen's proposition 5,6 which
assumes Pr{0 < Pr(Z = zs |𝜓 r(X))} = 1 and Pr{Pr(Z = zs |𝜓 r(X)) < 1} = 1. However, for multiple treatment exposures,
Pr{Pr(Z = zs |𝜓 r(X)) < 1} ≢ Pr{0 < Pr(Z = zr |𝜓 r(X))}.
2.4 Estimation of prognostic scores
For prognostic score analysis involving multiple exposures, the term “reference population” can be defined in multiple
ways. One option is to define the reference population from a pragmatic perspective by taking the population with the
largest sample size for fitting a prognostic score model. On the other hand, one could also define the reference population
as the patients who receive the standard treatment, primarily indicated in a given disease. Note that these two potential
reference populations generally coincide, as often the largest group of treated patients in observational studies will be
those receiving the standard care.
In practice, 𝜓 r(X) is unknown and therefore needs to be estimated from data at hand. The corresponding model can
be parametric, such that 𝜓r (X) = E(Yr|X, 𝛃). According to the outcome type (eg, continuous, binary, categorical, or
time-to-event), relevant regression models are to be considered (eg, linear, logistic, multinomial logistic, or proportional
hazards regression models). To fit 𝜓r (X), it is common to use only the reference arm of the data set that includes the
multiple exposures alongside, which is referred to as “same-sample estimation.” Alternatively, 𝜓r (X) can be derived from
a historical cohort of control subjects or from previously published prognostic models. Regardless of this choice, it is
important to fit a prognostic score to reference subjects only, that is, not to include individuals under other exposures.6
Otherwise, one would no longer estimate 𝜓 r(X).
In practice, the propensity score ês (X) = Pr(Z = zs|X, ?̂?) is often derived from maximum likelihood estimation. This
strategy is not to transpose to prognostic score modelling without precautions. Indeed, 𝜓r (X) = E (Yr|X, 𝛃) is to be
extrapolated to the different treatment exposure groups and thus requires that predictions from the prognostic score are
well calibrated in the corresponding subjects. Poorly calibrated prognostic scores may lead to improper matches, thereby
introducing confounding bias. In general, problems with calibration may arise when prognostic associations are biased
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(eg, due to overfitting or systematic measurement error), misspecified (eg, failure to account for nonlinear effects or inter-
actions) or omitted. It is therefore important to adopt robust estimation methods (eg, penalised regression) and to ensure
that prognostic scores properly account for prognostic factors that are likely to differ (eg, in distribution or measurement
method) across treatment exposures.
2.5 Conditioning on prognostic scores
For estimating causal effects, conditioning on propensity or prognostic scores often relies on subclassification ormatching
methods.
2.5.1 Subclassification
As in propensity score analysis, one can condition on the prognostic score (and effect modifier) by performing
subclassification.6,15,16 In this approach, individuals are parted into subclasses S ∈ {1,… ,Q}, within which the estimated
score 𝜓r (X) is roughly similar. Precedents have shown that subclassification by quintiles (ie, Q = 5) removed 90% of con-
founding bias when using propensity scores for binary treatments.15 After subclassification, one can approximate the
distribution of the potential outcomes asweightedmeans, withweights defined after the proportions of individuals falling
into subclasses.9 Let Si be the subclass of individual i. The average potential outcome Ys is estimated as{ Q∑
s=1
Ws
}−1 Q∑
s=1
{
Ws
∑N
i=1 I(Si = s)I(Zi = zs)Yi∑N
i=1 I(Si = s)I(Zi = zs)
}
.
Ws denotes the subclass weight, which is calculated as
Ws =
{∑N
i=1 I(Si = s)𝑓∑N
i=1 𝑓
}{ ∑N
i=1 I(Zi = zs)∑N
i=1 I(Si = s)I(Zi = zs)
}
.
To estimate the average potential outcome Ys in the entire population, the treated population (Z = zs), and the reference
population (Z = zr), we set f = 1, 𝑓= I(Zi = zs) and f = I(Zi = zr), respectively.
Estimating the potential responses across the multiple treatment exposures translates into dose-response relationships
in case of ordinal or continuous exposures. (Note that, in the latter, the use of a smoothing function might be of interest.)
We believe this approach to be robust because nonparametric and saved from model dependence.
In case of generalised propensity score analysis, subclassification depends on the treatment distribution and, thus, on
the propensity score models. For instance, for categorical treatments, estimated propensity scores can be derived from
multinomial logit or probit regressionmodels.9,10,17 Each treatment arm zs is then subclassified—separately—on the corre-
sponding propensity score, ês (X) = P̂r (Z = zs|X).16,18 Note that other treatments arms (Z ≠ zs) are also to be subclassified
on ês (X) in case one wants to estimate the distribution of Ys that would be observed if those populations were, contrary
to the fact, to receive zs. Using generalised prognostic score analysis, all treatment arms are to be subclassified on a same
prognostic score 𝜓r (X). Note, to estimate ATEs or ATRs in the presence of an effect modifier m(X), the subclassification
has to be made concurrently upon 𝜓r (X) andm(X). For instance, in case of a binary effect modifier, this would require to
double the number of subclasses.
2.5.2 Matching
In comparison to rough subclassification, matching methods aim to pair units that are “similar” with regard to the esti-
mated score. Previous works have presented reviews as to the role of matching for causal inference.19-21 Here, we focus
on matching methods that minimise a distance metric by sampling subjects without replacement. These methods may,
however, allow more than one individual per exposure arm to be involved in the matching. This implies that a paired set
could, for instance, consist of several (rather than one) control matches for a treated subject.
Let match(·) be a matching function of treatment exposure Z and distanceD, and ||·|| be a generic metric function. The
function match(zs, d) indexes byM =m,M ∈ {1,… ,K}, the individuals with exposure zs and minimal distance metric d
match (zs, d) = arg minm∶Zm=zs
‖Dm‖ .
Note that applying match(zs, d) to units under other exposures (Z≠ zs) leads to indexing them as if they were to receive zs.
As in subclassification, this procedure is necessary to estimate the distribution of the potential outcome Ys that would be
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observed in the other arms were they to be allocated zs. In the matching function, the distance refers to the “closeness”
between individuals within matched pairm and can be defined on the covariates X as
Dm = |Xm − x| .
The generic metric function ||·|| depends on the matching method. For instance, when performing covariate exact
matching on the covariates,
‖Dm‖ =
{
0, if Xm = x
∞, if Xm ≠ x,
Other common distance metrics are described in the literature, such as the Mahalanobis distance metric. If the distance
is instead defined as a scalar (eg, prognostic score 𝜓r (X) or propensity score ês (X)), then D becomes D. Generally, ||Dm||
is taken as ||Dm|| = Dm. For instance, using prognostic scores‖Dm‖ = Dm = |𝜓r (Xm) − 𝜓r (x)|.
Matching can be achieved upon a same prognostic score 𝜓r (X) in generalised prognostic score analysis, while using
generalised propensity scores requires individuals under exposure zs be matched on the corresponding propensity score
ês (X).16 Note, however, that in the presence of an effect modifierm(X), matching only on 𝜓r (X) is no longer sufficient for
estimating the ATE and ATR: One must then match on the combined set {𝜓r (X) ,m (X)}, which could in fact be scaled
on a propensity score ês (X) = P̂r(Z = zs|𝜓r (X) ,m (X)) (sometimes called “prognostic propensity score”). Notice that,
instead of using the scores themselves, particular functions can be used—eg, the logit of the propensity score.22
As when using subclassification, the distribution of the potential outcomes can then be approximated as weighted
means, with weights defined after the proportions of individuals falling into matched pairs. If Mi denotes the matched
pair unit i belongs to, then the average potential outcome Ys is estimated as{ K∑
m=1
Wm
}−1 K∑
m=1
{
Wm
∑N
i=1 I(Mi = m)I(Zi = zs)Yi∑N
i=1 I(Mi = m)I(Zi = zs)
}
.
Wm defines the pair weight
Wm =
{∑N
i=1 I(Mi = m)𝑓∑N
i=1 𝑓
}{ ∑N
i=1 I(Zi = zs)∑N
i=1 I(Mi = m)I(Zi = zs)
}
.
To estimate the average potential outcome Ys in the entire, the treated (Z = zs) and the reference (Z = zr) populations:
𝑓= 1, 𝑓= I(Zi = zs) and f = I(Zi = zr), respectively. Should we be interested in estimating the average potential outcome Ys
in the population receiving another exposure (Z = zt, ∀ t ≠ s ≠ r), then f = I(Zi = zt).
Again, a “pair” can comprise many individuals of same exposure arms as far as the specified distance is minimised.
Here, we focus on optimal full matching, the use of which is of great interest in case of binary treatment.23-25 Briefly, this
method involves the formation of “pairs” (or “strata”) consisting of either a single treated subject and one or more control
subjects, or a single control subject and one or more treated subjects. Subjects are paired such that their matched sets
are optimally balanced with regard to the distance metric.26 A key advantage of optimal full matching is that all subjects
are preserved in the analysis, thereby avoiding bias due to incomplete matching (which may, for instance, occur when
adopting 1:1:1 matching methods or callipers).
Because estimation of ATTs and ATRs requires conditioning on the prognostic score (and, if applicable, effect modifier)
across the reference and relevant exposure arms (ie, two paired arms), ATTs and ATRs can be estimated fairly straightfor-
ward in the presence of multiple treatment exposures as in binary treatments. However, to estimate the ATEs, one must
condition on the prognostic score (and effect modifier) with respect to its distribution in the entire population—that is,
perform an optimal full matching across all treatment arms. To the best of our knowledge, no such approach has yet been
described in the literature. We therefore propose to apply optimal full matching to the estimation of ATE in presence of
multiple treatment arms, as follows: Individuals under exposure zs are to be matched as would be those exposed to oth-
ers (Z ≠ zs)—regardless of the distinction between zt and zr (∀t ≠ s ≠ r)—were they to receive zs. Hence, each individual i
falls into a matched pair within which the distance in prognostic score 𝜓r (X) (or relevant propensity score ês (X)) is opti-
mally minimised. For each unit i andmatched pairm, I(Mi =m) is identifiable, and relevant weightsWm can therefore be
computed. Thus, one can estimate the distribution of Ys that would be observed if all treatment arms were to receive zs.
To estimate the distribution of the other potential outcomes under the different treatment exposures, the same approach
is to be used as described for Ys in this section. Using subclassification and optimal full matching, we conducted
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generalised prognostic score analyses in comparison to generalised propensity score analyses to estimate causal effects
through a series of simulations.
3 SIMULATION STUDY
In this section, we illustrate the use of prognostic scores for causal inference with multiple treatment exposures.
3.1 Data generation
We generated 10 independent variables X1,… ,X10, with X1,… ,X5 ∼N(0, 1); X5,… ,X8∼Binomial(0.3) and X9,
X10∼Binomial(0.5). We considered three treatment exposures A (“reference”), B, and C, and we generated the potential
outcomes (binary) as follows:
Pr (YA|X) = [1 + exp {− (−0.5X1 + 0.5X3 + 1.2X4 + 1.5X5 + 0.5X6 − 0.7X7 − X8 − 1.2X9 − 0.5X10)}]−1
Pr (YB|X) = [1 + exp(−0.25 + 1.15 log {Pr (YA|X)})]−1
Pr (YC|X) = [1 + exp(−0.5 + 0.65X10 log {Pr (YB|X)})]−1.
YA = 1, YB = 1 and YC = 1, if their respective probability was greater than a random number u, drawn from a Uniform
distribution U(0, 1). Note that equation for Pr(YC |X) included an effect modifier (X10) of C with respect to B and thus
also to A.
To mimic nonrandomised studies, we assigned the treatment exposure Z according to the covariates
LA = 0.9 + 0.30X1 + 0.50X2 + 0.70X3 + 0.90X4
LB = 0.2 + 0.10X1 + 0.20X2 + 0.30X3 + 0.40X9
Pr (Z = A|X) = exp (LA)1 + exp (LA) + exp (LB)
Pr (Z = B|X) = exp (LB)1 + exp (LA) + exp (LB)
Pr (Z = C|X) = 11 + exp (LA) + exp (LB) .
Using their respective probability, we sampledA, B, andCwith replacement to allocate the treatment. The actual outcome
was then generated using the equation:
Y = I (Z = A)YA + I (Z = B)YB + I (Z = C)YC.
Reiterating this process, we generated 1000 observational studies for the analyses, each including 2000 subjects. “True
values” of treatment effects were obtained from an independently drawn “superpopulation” including 5 000 000 subjects.
3.2 Analysis
In each observational study, we estimated the prognostic score by fitting a parametric logistic regression to the “reference”
arm, including all covariates X = (X1,… ,X10)
𝜓A (X) = Pr(Y |Z = A,X, 𝛃) = 1
1 + exp
{
−
(
𝛽0 +
∑Xp𝛽p)} .
This model was extrapolated to the other arms to predict the potential outcome that would have been observed, had they
received the reference exposure A. We then used two methods for conditioning: subclassification (by quintiles) and opti-
mal full matching (see Section 2.5). On the one hand, we conditioned on {𝜓A (X) ,X10}; on the other hand, we conditioned
on 𝜓A (X) only.
Using formulae described in Section 2.3, we estimated the effects of treatment exposuresZ=B andZ=C, with reference
to Z = A, as ATEs, ATTs, and ATRs (all on an absolute risk difference scale). Given the property of transitivity of ATEs
and ATRs (Section 2.1), we also computed the effect of Z = B in comparison to Z = C, as ÂTEB,C = ÂTEB,A − ÂTEC,A and
ÂTRB,C = ÂTRB,A − ÂTRC,A.
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In comparison to generalised prognostic score analysis, we conducted generalised propensity score analysis.9,10 Having
a categorical treatment, we fit a parametric multinomial logistic regression to estimate the propensity scores10,17
êA (X) = Pr(Z = A|X, ?̂?) = 11 + exp(𝛼B0 +∑Xp𝛼Bp) + exp(𝛼C0 +∑Xp𝛼Cp)
êB (X) = Pr(Z = B|X, ?̂?) = exp(𝛼B0 +∑Xp𝛼Bp)1 + exp(𝛼B0 +∑Xp𝛼Bp) + exp(𝛼C0 +∑Xp𝛼Cp)
êC (X) = Pr(Z = C|X, ?̂?) = exp(𝛼C0 +∑Xp𝛼Cp)1 + exp(𝛼B0 +∑Xp𝛼Bp) + exp(𝛼C0 +∑Xp𝛼Cp) .
We performed subclassification (by quintiles) and optimal full matching to condition on the propensity scores.
3.3 Results
On average, the prevalence to exposuresZ=A,Z=B andZ=Cwas equal to 49.3%, 29.1%, and 21.6%, respectively. The out-
come prevalence within each arm was equal to 40.2%, 13.3%, and 24.4%, respectively. (The naïve estimates corresponded
to the mere differences between these values.) All estimates of causal effects using the generalised propensity score and
the generalised prognostic score are reported in Table 1. Empirically, the estimators proposed in Section 2.3 allowed unbi-
ased estimation of the causal effects. As described in Section 2.3, conditioning on relevant effect modifiers, in addition
to the prognostic score, is necessary to estimate the ATEs and ATRs without bias. The property of transitivity held when
estimating these two treatment effects. (Note, for the internal validity of our simulations, we computed, along with the
transitive estimates of ATEs and ATRs, the corresponding matching/subclassification estimates; this resulted in a perfect
agreement. See Appendix 1 in Supplementary Material.) Generally, optimal full matching yielded higher mean squared
error (but lower bias) than subclassification. In this series of simulations, the use of generalised prognostic scores out-
performed that of generalised propensity scores in terms of bias, variance, and mean squared error (Table 1). The mean
squared errors obtained by generalised propensity score analysis was on average 149.9% higher than those obtained by
generalised prognostic score analysis, when conditioning on {𝜓A (X) ,X10}.
Figure 1 depicts the estimated average potential outcomes under treatment exposures A, B, andC after subclassifying on
both the prognostic score and the effectmodifierwith respect to their distribution in the entire population (ie, condition for
TABLE 1 Results of simulation study, when including all covariates in analysis. Bias (standard deviation, SD) and mean squared error
(MSE) of estimates
Generalised Propensity Score Analysis Generalised Prognostic Score Analysis
Subclassification Full Matching Effect Modifier Included Effect Modifier (Wrongfully) Ignored
Subclassification Full Matching Subclassification Full Matching
Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE
(SD) ×1000 (SD) ×1000 (SD) ×1000 (SD) ×1000 (SD) ×1000 (SD) ×1000
ATEB,A −0.009 0.5630 0.000 0.8365 −0.005 0.4758 −0.001 0.6147 −0.005 0.4711 −0.001 0.6287
(0.022) (0.029) (0.021) (0.025) (0.021) (0.025)
ATEC,A −0.006 0.9801 0.000 1.4452 −0.004 0.7696 0.002 1.3742 −0.001 0.7462 0.005 1.3731
(0.031) (0.038) (0.027) (0.037) (0.027) (0.037)
ATEB,C −0.002 0.9894 0.000 1.6867 −0.001 0.7523 −0.004 1.601 −0.004 0.7587 −0.006 1.6521
(0.031) (0.041) (0.027) (0.040) (0.027) (0.040)
ATTB,A −0.025 1.0862 −0.012 1.0001 −0.009 0.4613 0.000 0.546 −0.009 0.4552 0.000 0.5148
(0.022) (0.029) (0.020) (0.023) (0.020) (0.023)
ATTC,A 0.001 0.9062 0.017 1.6601 −0.009 0.8816 −0.001 0.9786 −0.009 0.8593 0.000 1.0116
(0.030) (0.037) (0.028) (0.031) (0.028) (0.032)
ATTB,C* - - - - - - - - - - - -
ATRB,A −0.005 0.9296 0.000 1.6029 −0.004 0.6137 −0.003 1.0326 −0.004 0.6086 −0.002 1.0608
(0.030) (0.04) (0.025) (0.032) (0.024) (0.033)
ATRC,A −0.004 1.8233 −0.003 2.7686 −0.002 0.9367 0.003 2.0917 0.003 0.9225 0.009 2.1526
(0.042) (0.053) (0.031) (0.046) (0.030) (0.046)
ATRB,C −0.001 2.1482 0.003 3.8504 −0.002 1.0113 −0.005 2.8026 −0.007 1.0396 −0.010 2.8889
(0.046) (0.062) (0.032) (0.053) (0.031) (0.053)
*Due to nontransitivity, ATTB,C was not estimated.
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FIGURE 1 Distribution of estimated potential outcomes after conditioning on the prognostic score and effect modifier, and the propensity
score. Red bold lines (ie, reference values) correspond to the expected values of potential outcomes obtained in an independent
“superpopulation” including 5 000 000 individuals. FM, full matching; SC, subclassification [Colour figure can be viewed at
wileyonlinelibrary.com]
TABLE 2 Results of simulation study, when omitting X3 (“true confounder,” ie, related to both exposures and potential outcomes) from all
analysis. Bias (standard deviation, SD) and mean squared error (MSE) of estimates
Generalised Propensity Score Analysis Generalised Prognostic Score Analysis
Subclassification Full Matching Effect Modifier Included Effect Modifier (Wrongfully) Ignored
Subclassification Full Matching Subclassification Full Matching
Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE
(SD) ×1000 (SD) ×1000 (SD) ×1000 (SD) ×1000 (SD) ×1000 (SD) ×1000
ATEB,A −0.027 1.1794 −0.020 1.1397 −0.024 1.0117 −0.020 1.0287 −0.024 1.0108 −0.020 1.0046
(0.022) (0.027) (0.021) (0.025) (0.021) (0.025)
ATEC,A −0.024 1.3804 −0.019 1.6438 −0.022 1.2041 −0.018 2.1513 −0.020 1.1351 −0.015 2.4085
(0.028) (0.036) (0.027) (0.043) (0.027) (0.047)
ATEB,C −0.003 0.8301 0.000 1.3966 −0.002 0.7148 −0.001 1.9575 −0.004 0.7208 −0.005 2.3173
(0.029) (0.037) (0.027) (0.044) (0.027) (0.048)
ATTB,A −0.046 2.5693 −0.037 2.2180 −0.029 1.2797 −0.022 1.0215 −0.029 1.2739 −0.022 1.0043
(0.021) (0.029) (0.020) (0.023) (0.020) (0.023)
ATTC,A −0.034 2.0128 −0.024 1.8702 −0.046 2.9076 −0.041 2.7115 −0.046 2.8738 −0.041 2.6661
(0.029) (0.036) (0.028) (0.032) (0.028) (0.031)
ATTB,C* - - - - - - - - - - - -
ATRB,A −0.015 0.9734 −0.009 1.4521 −0.015 0.7847 −0.013 1.1850 −0.015 0.7770 −0.013 1.1310
(0.027) (0.037) (0.024) (0.032) (0.023) (0.031)
ATRC,A −0.009 1.3518 −0.009 2.2235 −0.007 0.8858 −0.006 2.8341 −0.003 0.8345 0.001 3.3665
(0.036) (0.046) (0.029) (0.053) (0.029) (0.058)
ATRB,C −0.005 1.5374 0.000 2.9242 −0.008 0.9284 −0.007 3.3145 −0.012 0.9931 −0.013 3.9591
(0.039) (0.054) (0.029) (0.057) (0.029) (0.061)
*Due to nontransitivity, ATTB,C was not estimated.
estimating ATEs). This allowed us to directly assess the potential responses of the entire population to the three treatment
exposures; computing the average treatment effects was done by merely calculating the relevant differences across these.
Alternatively, we could have defined exposures A, B, and C as ordinal to visualise a dose-response relationship.
Results of additional simulations are reported in Tables 2 to 4, describing the impact of omitting some variables in
prognostic score modelling (eg, introduction of hidden bias) on the treatment effect estimation. Further simulations were
conducted in small samples, with results provided in Appendix 2 (Supplementary Material).
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TABLE 3 Results of simulation study, when omitting X6 (“prognostic variable,” ie, related only to potential outcomes) from all analysis.
Bias (standard deviation, SD) and mean squared error (MSE) of estimates
Generalised Propensity Score Analysis Generalised prognostic score analysis
Subclassification Full Matching Effect Modifier Included Effect Modifier (Wrongfully) Ignored
Subclassification Full Matching Subclassification Full Matching
Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE
(SD) ×1000 (SD) ×1000 (SD) ×1000 (SD) ×1000 (SD) ×1000 (SD) ×1000
ATEB,A −0.009 0.5702 0.000 0.8103 −0.005 0.4787 −0.002 0.6485 −0.005 0.4742 −0.001 0.6368
(0.022) (0.028) (0.021) (0.025) (0.021) (0.025)
ATEC,A −0.006 0.9832 0.000 1.4841 −0.004 0.7793 0.001 1.2774 −0.001 0.7520 0.005 1.3421
(0.031) (0.039) (0.028) (0.036) (0.027) (0.036)
ATEB,C −0.002 0.9811 0.000 1.6842 −0.001 0.7598 −0.003 1.4801 −0.004 0.7625 −0.006 1.5943
(0.031) (0.041) (0.028) (0.038) (0.027) (0.039)
ATTB,A −0.025 1.0852 −0.012 0.9704 −0.009 0.4608 0.000 0.5505 −0.009 0.4541 0.000 0.5192
(0.022) (0.029) (0.020) (0.023) (0.019) (0.023)
ATTC,A 0.001 0.9042 0.016 1.6300 −0.009 0.8740 −0.001 0.9912 −0.009 0.8486 0.000 1.0268
(0.030) (0.037) (0.028) (0.031) (0.028) (0.032)
ATTB,C* - - - - - - - - - - - -
ATRB,A −0.009 0.5702 0.000 0.8103 −0.005 0.4787 −0.002 0.6485 −0.005 0.4742 −0.001 0.6368
(0.022) (0.028) (0.021) (0.025) (0.021) (0.025)
ATRC,A −0.006 0.9832 0.000 1.4841 −0.004 0.7793 0.001 1.2774 −0.001 0.7520 0.005 1.3421
(0.031) (0.039) (0.028) (0.036) (0.027) (0.036)
ATRB,C −0.002 0.9811 0.000 1.6842 −0.001 0.7598 −0.003 1.4801 −0.004 0.7625 −0.006 1.5943
(0.031) (0.041) (0.028) (0.038) (0.027) (0.039)
*Due to nontransitivity, ATTB,C was not estimated.
TABLE 4 Results of simulation study, when omitting X2 (“instrumental variable,” ie, related only to exposures) from all analysis. Bias
(standard deviation, SD) and mean squared error (MSE) of estimates
Generalised Propensity Score Analysis Generalised Prognostic Score Analysis
Subclassification Full Matching Effect Modifier Included Effect Modifier (Wrongfully) Ignored
Subclassification Full Matching Subclassification Full Matching
Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE
(SD) ×1000 (SD) ×1000 (SD) ×1000 (SD) ×1000 (SD) ×1000 (SD) ×1000
ATEB,A −0.008 0.5453 0.000 0.7973 −0.005 0.4742 −0.001 0.6139 −0.005 0.4701 −0.001 0.6341
(0.022) (0.028) (0.021) (0.025) (0.021) (0.025)
ATEC,A −0.007 0.9263 −0.001 1.3437 −0.004 0.7590 0.002 1.2912 −0.001 0.7366 0.005 1.3531
(0.030) (0.037) (0.027) (0.036) (0.027) (0.036)
ATEB,C −0.002 0.9305 0.000 1.5498 −0.001 0.7497 −0.003 1.5167 −0.004 0.7570 −0.006 1.5963
(0.030) (0.039) (0.027) (0.039) (0.027) (0.040)
ATTB,A −0.022 0.9290 −0.009 0.8251 −0.009 0.4550 0.000 0.5000 −0.009 0.4478 0.000 0.5061
(0.021) (0.027) (0.020) (0.022) (0.019) (0.023)
ATTC,A −0.001 0.8189 0.013 1.5119 −0.009 0.8570 −0.001 0.9676 −0.009 0.8344 0.000 0.9533
(0.029) (0.037) (0.028) (0.031) (0.028) (0.031)
ATTB,C* - - - - - - - - - - - -
ATRB,A −0.006 0.8355 −0.001 1.4711 −0.004 0.6121 −0.002 1.0467 −0.004 0.6059 −0.002 1.0727
(0.028) (0.038) (0.024) (0.032) (0.024) (0.033)
ATRC,A −0.005 1.5473 −0.004 2.5417 −0.002 0.9275 0.002 1.9736 0.003 0.9174 0.009 2.1754
(0.039) (0.050) (0.030) (0.044) (0.030) (0.046)
ATRB,C −0.001 1.8331 0.002 3.4033 −0.002 1.0085 −0.004 2.6074 −0.007 1.0342 −0.011 2.8121
(0.043) (0.058) (0.032) (0.051) (0.031) (0.052)
*Due to nontransitivity, ATTB,C was not estimated.
4 STUDY CASE
As an illustrative case, we performed a subgroup analysis of the International Stroke Trial (IST), the data of which have
beenmade available in open access by the investigators.27 This trial included 19 435 patients across 36 countries and aimed
to estimate the effect of Aspirin (compared to non-Aspirin) on a primary composite outcome of death or dependence at
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6 months in stroke patients (binary outcome).28 Further details on the data set can be found elsewhere.27,28 Though the
IST was a randomised controlled trial, in this study case, we focused on the Aspirin arm only (9720 patients) as we were
interested in estimating the effect of the delay to Aspirin administration on the primary outcome. This delay varied from
1 to 48 hours from symptoms and likely depends upon clinical covariates (eg, stroke subtype, consciousness, executive
function deficits). Differences in these clinical characteristics are depicted in Figure 2, using standardised mean differ-
ences (SMD). At each time point, we calculated the covariate mean (approximated by p the proportion of the class, for
categorical/binary variables), which was then divided by the standard deviation (approximated by
√
p (1 − p) for categor-
ical/binary variables) obtained in the whole sample (ie, Aspirin arm). We computed SMDs, as the absolute differences in
those ratios (ie, standardised means), taking a delay of 24 hours as “reference.” As depicted in Figure 2, strong imbalance
(SMD > 0.25) occurred at very low or high delays, suggesting that patients receiving Aspirin very early or very lately were
likely to differ from those who received the treatment around 24 hours, in terms of clinical characteristics.
We performed both a generalised prognostic score analysis and a generalised propensity score analysis to estimate the
effect of the delay to Aspirin administration on the primary outcome.
For prognostic score analysis, we first derived a logistic regression model by maximum likelihood estimation as to the
risk of death or dependence at 6 months after Aspirin administration at 24 hours. We took this delay as “reference,” since
it included the largest sample size (809 patients), with 483 outcomes.We considered the following relevant confounders to
be entered into themodel: age, systolic blood pressure, sex, consciousness, previous computerised tomography (CT-scan),
visible infarct at CT-scan, stroke subtype, atrial fibrillation, Aspirin intake within the previous 3 days, and all function
deficits.We transposed the obtained prognostic score to other delay arms to predict the potential outcomes thatwould have
been observed, had all individuals received Aspirin at 24 hours. Using methods described in Section 2.5, we subclassified
and conducted an optimal full matching on the prognostic score to estimate the ATE. For matching, we considered 48
treatment exposures, each corresponding to their respective delay (in hours) of Aspirin administration. This enabled us
to investigate the entire function of treatment exposure. As described in Section 2.5.2, the prognostic score was matched
separately for each exposure group: we matched the individuals who received Aspirin at 1 hour to all the others; then,
those who received it at 2 hours to all the others; and so on. This allowed us to reweight all the treatment exposure groups,
as though they had similar distribution of the prognostic score as in the entire sample. We considered no effect modifiers
in this analysis.
In comparison, we performed a generalised propensity score analysis. Considering the delay as a continuous variable,
we derived a linear model by maximum likelihood estimation, including the same set of covariates as in the prognostic
score. Though the scalar returned by this linearmodel, 𝜃, does not represent the conditional probability of treatment delay
(ie, propensity score), Imai and van Dyk showed that, since the propensity function is characterised by 𝜃, conditioning
FIGURE 2 Difference in baseline characteristics expressed in standardised mean differences against delay (reference: 24-hour delay). Each
colour line denotes a covariate. Red bold dotted lines refer to common thresholds for considering imbalance [Colour figure can be viewed at
wileyonlinelibrary.com]
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FIGURE 3 Estimated risk of death or dependence at 6 months, given delay to Aspirin administration in stroke patients, by propensity and
prognostic score analyses. ARD, absolute risk difference per hour of delay [Colour figure can be viewed at wileyonlinelibrary.com]
on it allows one to condition on the propensity score.9 As for the generalised prognostic score, we conducted subclassifi-
cation and optimal full matching. Note that here, as opposed to ordinal or categorical multi-exposures which require to
match/subclassify on the respective propensity scores, all individuals are to be conditioned on 𝜃, regardless of the actual
delay.
In prognostic and propensity scores, continuous variable (age and systolic blood pressure) were modelled using a
restricted cubic spline with three knots. To address missing data (1067 missing values with regard to the outcome and rel-
evant covariates), we performed multiple imputation by chained equations, setting m = 10. Hereby, we adjusted for the
observed outcome and covariates used in the prognostic and propensity models. Furthermore, we adopted the strategy
recommended by Leyrat et al29: for each imputed dataset, we derived a prognostic score and a propensity score, matched
and subclassified on the scores, estimated the potential outcome distribution at each delay and the treatment effect (ie,
mean change to potential outcome across all delays, expressed in absolute risk difference); finally, we applied Rubin's
rules to average the estimates across the 10 data sets.
As depicted in Figure 3, the generalised prognostic and propensity score analyses yielded similar results. Using both
methods, we found no evident effect of the delay to Aspirin administration on the risk of death or dependence at 6months
in stroke patients. Like in the simulation study, subclassification resulted in less variance than optimal full matching,
regardless of the scores. Indeed, matching estimates were particularly scattered, as compared with those obtained by
subclassification. This poor performance was likely due to the substantial number of treatment exposures (ie, 48 time
points), which were to be matched separately.
5 DISCUSSION
In this article, we describe the theory of the prognostic score for causal inference with general treatment regimes and
propose estimators for different estimands of interest (Section 2), the validity of which is empirically verified through a
series of simulations (Section 3) and then illustrated in a study case (Section 4).
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We extend Hansen's formalisation of prognostic scores6 to allow investigation of multiple treatment exposures. The
proposed methods can be applied to compare multiple treatments using nonrandomised data, a topic of great relevance
in contemporary evaluations of clinical interventions. Similarly to the propensity score, the prognostic score reduces the
dimension of multiple subject covariates into a single, summarising score that can be used for matching or subclassifica-
tion. While the primary purpose of the propensity score is to balance the covariate across the treatment arms as would
do a randomised experiment,5 conditioning on a prognostic score aims to approximate an experimental design in which
subjects would share similar potential responses to treatments at baseline.6 The use of the propensity score for causal
inference with general treatment regimes has been defined elsewhere,9,10 yet not the use of the prognostic score. In the
pharmacoepidemiology literature, a previous simulation study attempted to compare the performance of multivariable
regression, propensity, and prognostic scores in case of multiple treatment exposures.30 However, it remained unclear—to
the best of our understanding—which estimand was of interest (ATE, ATT, ATR, marginal or conditional effect) and how
the performance, related to a true causal effect, was measured. Nor was it evident to us why the authors chose to fit a
prognostic model to the overall sample, instead of deriving it from reference subjects only, as recommended.6 In his arti-
cle, Hansen clearly cautioned against the fitting of a model to the entire sample (including both reference and treated
subjects), for it does no longer allow the estimation of the true prognostic score 𝜓 r(X) but a mixture of propensity and
prognostic scores influenced by potential outcomes under nonreference exposures.6
In the present article, we show that the framework of prognostic scores can easily be transposed to multiple treatment
exposures, by relating to the propositions and assumptions applicable to the case of binary treatments. In multiple treat-
ment exposures, the generalised propensity score involves either the estimation of the multivariate conditional density
of Z given X, or the fitting of a parametric model (depending on the treatment exposure distribution), which requires the
assumption of uniquely parameterised propensity function.9 In contrary, the generalised prognostic score is estimated
in a way akin to the case of binary treatment, regardless of the exposure distribution—be it categorical, ordinal, or con-
tinuous. A prognostic model is still to be fitted to some reference subjects (originating from same sample as treated or
from historical cohorts), before being extrapolated to subjects receiving different treatment exposures. In addition, the
positivity assumption required for generalised propensity score analysis is relaxed in generalised prognostic score anal-
ysis: The former requires Pr (Z ∈ Z|X) > 0 for all X ∈ A,9 while the latter demands Pr (Z ∈ Z|𝜓r (X) ,m (X)) > 0. Note
that this relaxation is even stronger in case of multiple treatment exposures, since positive measures are necessitated in
dimZ (Z) × dimA (X) dimensions for generalised propensity score, compared to dimZ (Z) × (1 + F) dimensions for gen-
eralised prognostic score (F being the number of effect modifiers). Thus, the generalised propensity score is likely to
suffer more from the curse of dimensionality. In that sense, the generalised prognostic score offers advantages over the
generalised propensity score from an analytic perspective.
As shown in Section 2.5, conditioning on the generalised prognostic score via subclassification or matching is straight-
forward as in the case of binary treatments. Each exposure arm is to be subclassified (or matched) on a same prognostic
score, as opposed to subclassification (or matching) on the generalised propensity score, which must be done on the
relevant, corresponding exposure propensity score. An alternative offered to the generalised propensity score analysis,
which is not directly applicable to the generalised prognostic score, is weighting on the inverse probability of treatment
exposure.17 However, a recent simulation study demonstrated that this approach offers no substantial advantages over
subclassification or matching.16 Empirical results reported in Section 3 suggest that—using the same variable set in score
modelling and the same methods for conditioning (subclassification or full matching)—the generalised propensity score
analysis generally leads to higher variance in treatment effect estimations than does the generalised prognostic score
analysis. This might be due to the fact that, in case of a binary outcome and T treatment arms, a multinomial logis-
tic propensity score model fits T − 1 equations and is therefore likely to consume much more degrees of freedom (ie,
(T − 1)(k + 1) d.f., for 1 intercept and k regression coefficients) than a binary logistic prognostic model (ie, (k + 1) d.f.).
(Note that this does not hold in case of continuous treatment regimes, as in the study case, for it is sufficient for propensity
score analysis to condition on the scalar, 𝜃, estimated by linear regression using (k + 1) d.f.) Furthermore, the gener-
alised propensity score suffers from an additional issue that is not relevant when dealing with two treatment exposures.
In binary treatment exposures (ie, Z ∈ {0, 1}), subclassifying/matching on ê1 (X) = P̂r (Z = 1|X) is similar to subclassi-
fying/matching on ê0 (X) = P̂r (Z = 0|X), since ê1 (X) = 1 − ê0 (X). This does not hold in case of multiple treatment
exposures, where subclassification/matching relies on propensity scores that are “extrapolated” to predict the exposure
probability in the corresponding, but also in the different treatment arms. In this sense, the generalised propensity score
presents no advantage over the prognostic score as it does in binary treatment arms. Further studies are thus needed to
compare the relative performance between generalised propensity score analysis and its prognostic analogue in scenarios
in which—albeit relatively uncommon in clinical practice—the exposures would be limited to but a few treatment arms
and the outcome would include numerous categories. (Note, in this case, the prognostic scores would be no longer scalar
but multidimensional.)
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A common approach to estimating treatment effects is to adopt “traditional” regression adjustment methods. Although
this strategy is relatively straightforward, its implementation may be problematic in practice because treatment effect
estimates are directly affected by changes in model specification (eg, interaction or continuous variable functional spec-
ification). For instance, Ho et al showed that adjusting for a continuous confounder could lead to conflicting estimated
treatment effects (ie, positive or negative effects), depending on whether the analyst chose a linear or a quadratic model.31
Propensity score and prognostic scoremethods rely on a different paradigm: They aim to restore a formof balancewhich is
sufficient for causal inference, such that treatment effect estimation requires no model specification but a mere marginal
difference in observed outcomes. This balance is attained by minimising a distance—namely, propensity or prognostic
distance—between individuals under different exposures. In this sense, propensity and prognostic scores limit model
dependence for they do not allow the analyst to directly specify the relationship between the treatment effect and the
outcome.
In practice, balance of the propensity score can be assessed in the entire sample. Conversely, for the prognostic score,
balance is merely assumed, as it is impossible to assess whether individual predicted potential outcomes for nonobserved
treatment exposures are correct. A recent study has investigated the use of “dry-run” analysis to address this issue.32 In
the predictive modelling literature, it is known that applying a prognostic model to an external populationmight lead to a
decreased predictive accuracy when differences in covariate distributions or in predictor-outcome associations occur.33 In
nonrandomised studies, it is most likely that subjects receiving alternative (eg, experiential) treatments differ from those
assigned to the reference (eg, standard care). It is thus of uttermost importance to build prognostic models that account
for the relevant covariates (ie, assumption of no hidden bias) but at the same time avoid overfitting. Otherwise, such an
approach would be reduced back to model dependence, the issue of which matching and propensity score analysis are
specifically aimed at avoiding.31 Since the prognostic score has to be fitted to a reference group, deriving a same-sample
modelmay become difficult in the presence ofmany exposure arms (eg, continuous treatments). In such cases, prognostic
models derived on historical cohorts of reference subjectsmay be regarded as an interesting alternative. According to a few
simulation studies,6,34-37 the latter is deemed asmore robust an approach than the former, even in case of binary exposures,
in the sense that—being less concerned by overfitting—it might enable a better extrapolation of 𝜓r (X) = E(Yr|X, 𝛃) to
the treated arms, thereby allowing a more desirable prognostic balance. The development of advanced prognostic models
might further be improved by considering evidence synthesis, either using patient-level data or (previously published)
aggregate data from multiple studies.33,38-43 We will investigate these strategies in the near future.
To the absence of hidden bias also required in propensity score analysis, the prognostic score analysis entails an addi-
tional assumption in estimating the ATEs andATRs: Onemust be able to identify all effect modifier(s), since conditioning
on them along with the prognostic score is necessary. This seems of particular importance, for ATEs and ATRs are transi-
tive estimands which allow direct comparisons of nonreference treatment effects. In contrary, estimating the ATTs does
not require conditioning on any effect modifiers; yet it provides limited interpretation on causal effects that are inferred
upon different populations across which comparisons are unlikely to be relevant. However, as discussed by some authors,
it is sometimes of great interest to estimate the treatment effect in those for whom the treatmentwas intended44; situations
for which the use of prognostic scores appears most appealing.
In response to these issues, further research is needed to improve the practical use of the generalised prognostic score.
First, one should investigatewhether robust regressionmethods, eg, involving penalisation, improve the predictive perfor-
mance of prognostic scoremodels when applied to new (ie, treated) subjects. Second, extending the joint use of propensity
and prognostic scores45 to general treatment regimes might be of interest as it would enable the causal effect estima-
tion to rely on the accuracy of, at least, only one of the two components (“double robustness”). Note, conditioning on
the propensity score es(X) = Pr(Z = zs |X) would result in Ys ⟂ Z | es(X), if Ys ⟂ Z |X (ie, in the absence of unmeasured
confounders related to Ys and Z). Hence, as suggested by a reviewer, the joint use of 𝜓 r(X) and es(X) would enable the
estimation of ATRs and ATEs by ensuring that (Yr,Ys) ⟂ Z | (𝜓 r(X), es(X)). Similarly, ATRs and ATEs could be estimated
by conditioning on two (rather than one) prognostic scores 𝜓 r(X) = E(Yr |X) and 𝜓 s(X) = E(Ys |X). This would then
result in (Yr,Ys) ⟂ Z | (𝜓 r(X),𝜓 s(X)), if additionally to Yr ⟂ Z |X we had Ys ⟂ Z |X. In both cases, the joint use of several
scores demands additionalmodelling steps and a slightly stronger form of the assumption of no unmeasured confounders.
Finally, further research is needed to allow direct estimation of standard errors of estimated treatment effects. These esti-
mates are particularly relevant when comparing causal effects across nonreference exposures, as allowed by the property
of transitivity of ATEs andATRs. Althoughwe did not evaluate this here, one (rather time-consuming) common approach
might be to adopt bootstrapping—the limitations of which have been discussed for matching estimators.46
Since several precautions have been raised, one should carefully weigh up the pros and cons of performing the gener-
alised prognostic score over the generalised propensity score analysis. On the one hand, the prognostic score seems more
appealing when facing a large number of exposures as it enables the estimation of ATEs, ATRs, and notably, ATTs, while
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being less dependent on the positivity assumption. (Note, as raised by a reviewer, since the prognostic score assumes
Yr ⟂ X ∣ 𝜓 r(X), it may require that Pr(Yr ∈ ·|X) > 0, that is, another form of positivity). Deriving a prognostic score for
a common reference treatment can, however, be challenging as it may dramatically reduce the effective sample size. A
second limitation of generalised prognostic score is that estimation of ATEs and ATRs is difficult in the presence of mul-
tiple (continuous) effect modifiers. For this reason, the generalised prognostic score may be more appealing when ATTs
are of primary interest, or when there is limited evidence of effect modification. In general, we believe that both methods
should be regarded as complementary rather than exclusive, which warrants the need for further research to extend their
combined use to general treatment regimens (“generalised prognostic propensity score analysis”).
In conclusion, this article presents an extension of the framework proposed by Hansen, on the use of prognostic scores
for causal inference in binary treatments,6 to the case of general treatment regimes.
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